Literature DB >> 31866246

Identification and Characterization of Unique Neutralizing Antibodies to Mouse EGF Receptor.

Won Jae Huh1, Hiroaki Niitsu2, Brandon Carney3, Eliot T McKinley4, Jacob L Houghton3, Robert J Coffey5.   

Abstract

Entities:  

Keywords:  Colorectal Cancer; EGFR; MM-151; Ménétrier's Disease

Mesh：

Substances：

Year:  2019        PMID： 31866246      PMCID： PMC7103561          DOI： 10.1053/j.gastro.2019.12.017

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  9 in total

1.  Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.

Authors:  Mace L Rothenberg; Bonnie LaFleur; Donna E Levy; Mary Kay Washington; Sherry L Morgan-Meadows; Ramesh K Ramanathan; Jordan D Berlin; Al B Benson; Robert J Coffey
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

2.  Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.

Authors:  Jeffrey D Kearns; Raghida Bukhalid; Mark Sevecka; Gege Tan; Nastaran Gerami-Moayed; Shannon L Werner; Neeraj Kohli; Olga Burenkova; Callum M Sloss; Anne M King; Jonathan B Fitzgerald; Ulrik B Nielsen; Beni B Wolf
Journal:  Mol Cancer Ther       Date:  2015-04-24       Impact factor: 6.261

3.  Efficacy of cetuximab in the treatment of Menetrier's disease.

Authors:  William H Fiske; Jarred Tanksley; Ki Taek Nam; James R Goldenring; Robbert J C Slebos; Daniel C Liebler; Amir M Abtahi; Bonnie La Fleur; Gregory D Ayers; Christopher D Lind; Mary K Washington; Robert J Coffey
Journal:  Sci Transl Med       Date:  2009-11-25       Impact factor: 17.956

4.  EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer.

Authors:  Yasuyuki Okada; Tetsuo Kimura; Tadahiko Nakagawa; Koichi Okamoto; Akira Fukuya; Takahiro Goji; Shota Fujimoto; Masahiro Sogabe; Hiroshi Miyamoto; Naoki Muguruma; Yasushi Tsuji; Toshiya Okahisa; Tetsuji Takayama
Journal:  Mol Cancer Res       Date:  2017-07-11       Impact factor: 5.852

5.  A Chimeric Egfr Protein Reporter Mouse Reveals Egfr Localization and Trafficking In Vivo.

Authors:  Yu-Ping Yang; Haiting Ma; Alina Starchenko; Won Jae Huh; Wei Li; F Edward Hickman; Qin Zhang; Jeffrey L Franklin; Douglas P Mortlock; Sabine Fuhrmann; Bruce D Carter; Rebecca A Ihrie; Robert J Coffey
Journal:  Cell Rep       Date:  2017-05-09       Impact factor: 9.423

6.  Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.

Authors:  Lilach M Friedman; Ariel Rinon; Bilha Schechter; Ljuba Lyass; Sara Lavi; Sarah S Bacus; Michael Sela; Yosef Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

7.  Loss of Lrig1 leads to expansion of Brunner glands followed by duodenal adenomas with gastric metaplasia.

Authors:  Yang Wang; Chanjuan Shi; Yuanyuan Lu; Emily J Poulin; Jeffery L Franklin; Robert J Coffey
Journal:  Am J Pathol       Date:  2015-04       Impact factor: 4.307

8.  Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

Authors:  Mikkel Wandahl Pedersen; Helle Jane Jacobsen; Klaus Koefoed; Adam Hey; Charles Pyke; John Sørensen Haurum; Michael Kragh
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

9.  MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

Authors:  Sabrina Arena; Giulia Siravegna; Benedetta Mussolin; Jeffrey D Kearns; Beni B Wolf; Sandra Misale; Luca Lazzari; Andrea Bertotti; Livio Trusolino; Alex A Adjei; Clara Montagut; Federica Di Nicolantonio; Rachel Nering; Alberto Bardelli
Journal:  Sci Transl Med       Date:  2016-02-03       Impact factor: 17.956
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.